Our proprietary drug discovery Kinase Switch Control platform is based on our deep insight into the biology of kinases. The transformation of a kinase from an inactive to an activated state is dependent upon the interaction of one region of the kinase called the activation switch with an area called the switch pocket; a mechanism of activation that is common among kinases. By directly targeting the switch pocket, we design inhibitors to be broadly active against the target kinase, covering both wild-type and many or all of the known mutant or amplified forms, or spectrum-selective towards several chosen kinases.
While this activation mechanism is common among kinases, the molecular structure of the activation switch and the switch pocket varies among kinases. At Deciphera, we take advantage of this variation to design molecules that inhibit a specific kinase or kinases.
We believe no other kinase inhibitors on the market or active in clinical development directly target the switch pocket region, making Deciphera the only biopharmaceutical company that is currently developing kinase inhibitors using this approach. Our kinase switch control inhibitors interact at a molecular level that is distinct from other kinase inhibitors and are designed to generate higher and more durable rates of response as compared to other kinase inhibitors. Using our kinase switch control inhibitor platform, we have developed a diverse pipeline of differentiated, wholly-owned, orally administered drug candidates that include three clinical-stage and two research-stage programs.